莱弗卢诺胺作为一种替代性治疗类风湿性关节炎的药物在资源有限的环境中:现实生活中的经验
1Division of General Medicine, Department of Medicine, Faculty of Medicine and Health Sciences, Tygerberg Academic Hospital and Stellenbosch University, Cape Town, South Africa.
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
|December 11, 2025
概括
勒弗卢诺胺 (LEF) 是一种有效的替代方案,用于类风湿性关节炎 (RA) 患者,这些患者对甲状腺酸 (MTX) 没有反应. 这项研究表明,LEF显著降低了疾病活动,在没有生物治疗的情况下提供了有价值的选择.
科学领域:
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 甲托雷克萨特 (MTX) 是类风湿性关节炎 (RA) 的主要治疗方法.
- 生物疾病修饰性抗风湿药物 (bDMARDs) 建议用于具有不良预后因素的MTX不响应者.
- 在非洲环境中,bDMARDs往往无法获得,因此需要替代治疗.
研究的目的:
- 为了评估Leflunomide (LEF) 在低资源环境中的有效性和安全性.
- 评估LEF对RA患者的实用性,RA患者对MTX的反应不足.
- 确定LEF作为替代常规合成DMARD (csDMARD) 的作用.
主要方法:
- 对210名RA患者的回顾性审查,这些患者至少6个月 (2018-2020年) 用LEF治疗.
- 收集的数据包括人口统计数据,LEF启动的原因,副作用和停药率.
- 使用临床疾病活动指数 (CDAI) 评估的有效性,每6个月间隔至24个月.
主要成果:
- 99.52%的患者有不良预后因素,疾病活性较高 (平均CDAI为26.68).
- 治疗LEF导致平均CDAI显著降低至11.17 (p<0.001).
- 53%的患者实现了治疗目标,包括临床缓解 (11.9%) 和低疾病活性 (41.1%).
结论:
- 莱弗卢诺胺 (LEF) 是一种有效的cDMARD,用于RA患者,对基于MTX的疗法反应不足.
- 在RA患者中,LEF显著降低了疾病活性 (平均CDAI从26降至11).
- 对于那些预后不佳且无法获得bDMARDs的RA患者来说,LEF提供了一个可行的替代方案.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
459
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
459
01:21Rheumatic Heart Disease III: Medical Management
264
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
264
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
408
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
408
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
445
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
445
01:23Rheumatic Heart Disease I: Introduction
407
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
407
01:29Therapeutic Drug Monitoring: Affecting Factors
175
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
175